Biocon wins US FDA approval for Pebrilzo breast cancer biosimilar
Biocon Biologics secured U.S. FDA approval for Pebrilzo, a biosimilar to Perjeta for HER2-positive breast cancer. The earliest licensed U.S. launch is in the third quarter of 2028 under a settlement with Genentech.
1. FDA approval and launch
Biocon Biologics secured U.S. FDA approval for Pebrilzo, a biosimilar to Perjeta for treating HER2-positive breast cancer. Under a settlement with Genentech, the earliest licensed U.S. launch is in the third quarter of 2028.





